Journals / İnönü üniversitesi Sağlık Hizmetleri Meslek Yüksek Okulu Dergisi / 2020 / Cilt: 8 - Sayı: 3

Kawasaki Disease and Dental Approaches

KAWASAKİ HASTALIĞI VE DENTAL YAKLAŞIMLAR

Pages
989–1001
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this review is to share current information about KD which has come to the agenda during the COVID-19 pandemic that affected the world, and to guide the dentist's approaches during dental treatment of these patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is a self-limiting medium-sized muscular artery vasculitis and is the most common cause of acquired heart disease in children in developed countries.
📊
Key Findings & Data:The disease mostly affects children under 5 years old.
💡
Conclusion & Impact:The aim of this review is to share current information about KD which has come to the agenda during the COVID-19 pandemic that affected the world, and to guide the dentist's approaches during dental treatment of these patients.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:ÇOCUKLUK HASTALIKLARI · DENTAL YAKLAŞIMLAR · KAWASAKİ HASTALIĞI

Abstract

Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is a self-limiting medium-sized muscular artery vasculitis and is the most common cause of acquired heart disease in children in developed countries. The disease mostly affects children under 5 years old. In the treatment of KD, use of intravenous immunoglobulin (IVIG) together with acetylsalicylic acid (ASA) is accepted as the standard treatment. Early diagnosis and treatment is very important in this childhood disease, which has life-long complications such as thrombosis, coronary stenosis, myocardial infarction, calcifications, the rupture of giant coronary artery aneurysm and sudden death. The frequent occurrence of oral symptoms in KD indicates that pediatric dentists may play a role in the diagnosis of KD. Also, the symptoms, treatment and complications of KD affect the approach of dentists to patients during dental treatment procedures. The aim of this review is to share current information about KD which has come to the agenda during the COVID-19 pandemic that affected the world, and to guide the dentist's approaches during dental treatment of these patients.

Özet

Mukokutanöz lenf nodu sendromu olarak da bilinen Kawasaki hastalığı (KH), kendini sınırlayan orta çaplı musküler arter vasküliti olup, gelişmiş ülkelerdeki çocuklarda edinilmiş kalp hastalığının en yaygın nedenidir. Hastalık çoğunlukla 5 yaşın altındaki çocukları etkiler. KH’ nin tedavisinde intravenöz immünoglobulin (IVIG) ile birlikte asetil salisilik asit (ASA) kullanımı standart tedavi olarak kabul edilir. Yaşam boyu tromboz, koroner stenoz, miyokard enfarktüsü, kalsifikasyonlar, dev koroner arter anevrizması rüptürü ve ani ölüm gibi komplikasyonları olan bu çocukluk çağı hastalığının, erken tanı ve tedavisi çok önemlidir. KH’ de oral bulguların sıkça görülmesi, özellikle pediatrik diş hekimlerinin KH tanısında rol alabileceğini gösterir. Ayrıca KH bulguları, tedavisi ve komplikasyonları dental tedavi prosedürleri sırasında diş hekimlerinin hastalara yaklaşımlarını etkiler. Bu derlemenin amacı, tüm dünyayı etkileyen COVID-19 pandemisi döneminde yeniden gündeme gelen KH hakkındaki güncel bilgileri paylaşmak ve bu hastaların dental tedavileri sırasında diş hekimlerinin yaklaşımlarına yol gösterici olmaktır.

🔖

Cite This Article

CANDAN, M., İPEK, İ., ÜNAL, M. (2022). Kawasaki Disease and Dental Approaches. İnönü üniversitesi Sağlık Hizmetleri Meslek Yüksek Okulu Dergisi, Cilt: 8 - Sayı: 3, 989–1001. https://ajindex.com/articles/548381

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Asano, T., Ogawa, S. (2000). Expression of monocyte chemoattractant protein-1 in Kawasaki disease: The anti-inflammatory effect of gamma globulin therapy. Scandinavian Journal of Immunology, 51(1), 98-103.
  2. Cahill, T. J., Harrison, J. L., Jewell, P., Onakpoya, I., Chambers, J. B., Dayer, M., … Prendergast, B. D. (2017). Antibiotic prophylaxis for infective endocarditis: A systematic review and meta-analysis. Heart (British Cardiac Society), 103(12), 937-944.
  3. Chambers, S. T., Murdoch, D., Morris, A., Holland, D., Pappas, P., Almela, M., …International Collaboration on Endocarditis Prospective Cohort Study Investigators. (2013). HACEK infective endocarditis: Characteristics and outcomes from a large, multi-national cohort. PloS One, 8(5), e63181. Chapman, J., Arnold, J. K. (2020). Reye Syndrome. Içinde StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK526101/
  4. Denby, K. J., Clark, D. E., Markham, L. W. (2017). Management of Kawasaki disease in adults. Heart (British Cardiac Society), 103(22), 1760-1769.
  5. Furukawa, S., Matsubara, T., Umezawa, Y., Okumura, K., Yabuta, K. (1994). Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. The Journal of Pediatrics, 124(5 Pt 1), 721-725.
  6. Holman, R. C., Christensen, K. Y., Belay, E. D., Steiner, C. A., Effler, P. V., Miyamura, J., … Melish, M. (2010). Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Medical Journal, 69(8), 194-197.
  7. Jones, V. G., Mills, M., Suarez, D., Hogan, C. A., Yeh, D., Bradley Segal, J., … Mathew, R. (2020). COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. Hospital Pediatrics,10(6), 537-540.
  8. Kumrah, R., Vignesh, P., Rawat, A., Singh, S. (2020). Immunogenetics of Kawasaki disease. Clinical Reviews in Allergy & Immunology, 59, 122–139.
  9. Magrum, B. G., Pickworth, K. K. (2020). Aspirin rechallenge in an adult patient previously diagnosed with Reye syndrome. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists, 77(2), 123-127.
  10. Makino, N., Nakamura, Y., Yashiro, M., Ae, R., Tsuboi, S., Aoyama, Y., … Yanagawa, H. (2015). Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: From the results of the 22nd nationwide survey. Journal of Epidemiology, 25(3), 239-245.
  11. McCrindle, B. W., Rowley, A. H., Newburger, J. W., Burns, J. C., Bolger, A. F., Gewitz, M., … American Heart Association Rheumatic Fever, Endocarditis, and Ka